Singapore markets closed
  • Straits Times Index

    3,166.27
    -55.25 (-1.72%)
     
  • Nikkei

    28,751.62
    -747.66 (-2.53%)
     
  • Hang Seng

    24,080.52
    -659.64 (-2.67%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • BTC-USD

    54,415.76
    -2,533.58 (-4.45%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Gold

    1,785.50
    +1.20 (+0.07%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • FTSE Bursa Malaysia

    1,512.22
    -5.38 (-0.35%)
     
  • Jakarta Composite Index

    6,561.55
    -137.79 (-2.06%)
     
  • PSE Index

    7,278.44
    -90.83 (-1.23%)
     

Global High Potency Active Pharmaceutical Ingredients Market to 2028 - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

·3-min read

DUBLIN, October 20, 2021--(BUSINESS WIRE)--The "High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biotech), By Manufacturer Type (In-house, Outsourced), By Drug Type, By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global high potency active pharmaceutical ingredients market size is expected to reach USD 38.84 billion by 2028, according to a new report by the publisher It is expected to expand at a CAGR of 8.4% from 2021 to 2028. The market is driven by an increased focus on targeted therapies and a surge in demand for cancer therapies.

The rising prevalence of cancer is a major factor expected to drive the market for high potency active pharmaceutical ingredients (HPAPIs). According to the WHO, cancer is the second biggest cause of death, causing over 9.6 million deaths in 2018 and the use of tobacco is responsible for 22% of cancer deaths. As per the CDC, the risk factors such as lifestyle changes including smoking, obesity, alcohol consumption, and exposure to UV radiation from the sun or tanning beds have contributed to the overall burden of the disease. Moreover, the cost of cancer care is anticipated to reach USD 174 billion by the end of 2020, which is anticipated to accelerate the market growth.

Increased demand for antiviral drugs such as remdesivir for COVID-19 treatment is fueling the demand for high potency antiviral HPAPIs. The change in supplier dynamics owing to COVID-19 and the increased focus of governments on pharmaceutical raw materials, such as HPAPIs, are driving the market.

Japan and China are among the leading countries with numerous biotech companies involved in the production of HPAPIs. The presence of major companies such as Takeda and Sankyo has boosted the development of biotechnology-derived APIs in these countries. Furthermore, the growth of the biotech segment can be attributed to the high investments in the biotechnology and biopharmaceutical sectors. This allows the innovation of new molecules that aid in the treatment of diseases, such as cancer.

Key players are leveraging various strategies to increase their production capabilities and promote the outreach of their product offerings. For instance, in July 2020, CordenPharma International announced the expansion of its peptide manufacturing unit in Colorado to address the increased demand for peptide APIs. This expansion will enable the company to grow and help in generating increased revenue.

High Potency Active Pharmaceutical Ingredients Market Report Highlights

  • In 2020, the synthetic product segment held the largest share of over 70.0% owing to the easy availability of raw materials and highly developed manufacturing systems

  • By manufacturer type, the outsourced segment is projected to grow at the fastest rate over the forecast period

  • Based on drug type, the innovative segment held the largest revenue share in 2020 owing to the increased focus on R&D

  • In terms of application, the oncology segment dominated the HPAPIs market in 2020 owing to the rising incidence of cancer worldwide

  • Asia Pacific is expected to witness the fastest growth during the forecast period due to the improving manufacturing infrastructure and the presence of numerous generic HPAPI manufacturing companies

Market Dynamics

Drivers

  • Rising prevalence of cancer

  • Growth of targeted therapies

  • Increasing application of HPAPIs

Restraints

  • Large investments and very stringent safety and handling specifications associated with the production of HPAPIs

Companies Mentioned

  • BASF SE

  • CordenPharma International

  • Dr. Reddy's Laboratories Ltd.

  • Carbogen Amcis AG

  • Pfizer Inc.

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Albany Molecular Research Inc.

  • Sanofi

  • Merck & Co., Inc.

  • Novartis AG

  • F. Hoffmann-La Roche Ltd.

  • Bristol-Myers Squibb Company

  • Boehringer Ingelheim GmbH

  • Lonza

  • Cipla Inc.

For more information about this report visit https://www.researchandmarkets.com/r/49cgbj

View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005618/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting